Shares of Moleculin Biotech Inc. (MBRX) are suring over 38% in pre-market today, following the company's agreement with Sterling Pharma USA LLC for US production of WP1122 to support its expanded development efforts in preparation for submitting the FDA request for Investigational New Drug or IND status for WP1122 for the potential treatment of COVID-19.
from RTT - Before the Bell https://ift.tt/32oF7Gz
via IFTTT
No comments:
Post a Comment